🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Düsseldorf
Clinical trial register · Germany

Clinical Trials in Düsseldorf, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Heinrich-Heine University, Duesseldorf43 AstraZeneca20 Merck Sharp & Dohme LLC13 Hoffmann-La Roche13 Janssen Research & Development, LLC8
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Düsseldorf

420 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care
NCT07699640Testicular Cancer, Testicular Germ Cell Tumor
Heinrich-Heine University, Duesseldorf
Not applicable
171
Ulm, Würzburg, Hamburg, Marburg, Cologne, Düsseldorf, Wuppertal, Dresden
2027-01
Not yet open
ESR1Real World Assessment Prevalence Study
NCT07817212HR+/HER2- aBC Undergoing 1L Treatment With CDK4/6i (Palbociclib, Abemaciclib or Ribociclib) and AI (Anastrozole or Letrozole)
Institut fuer Frauengesundheit
Not applicable
1,550
Ansbach, Bremen, Celle, Dresden, Düsseldorf, Erlangen, Homburg, Ilsede
2026-10-01
Not yet open
Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial
NCT07788586Candidemia, Invasive Candidiasis
Oliver Cornely, MD
Phase 4
420
Aachen, Berlin, Cologne, Dresden, Düsseldorf, Frankfurt am Main, Freiburg im Breisgau, Giessen
2026-09
Recruiting
Exercise, Chronotype, and Prediabetes
NCT07389005Prediabetes, Overweight , Obesity
German Diabetes Center
Not applicable
28
Düsseldorf
2026-09
Recruiting
PULSed Field Ablation for Atrial Fibrillation Using a Balloon for Early Intervention - Study
NCT07621003Atrial Fibrillation
Asklepios proresearch
Not applicable
264
Bad Oeynhausen, Cologne, Düsseldorf, Frankfurt, Giessen, Hamburg, Herne, Leipzig
2026-08-19
Not yet open
Do Immediate Digital Workflows Increase Patient Value?
NCT07656597Dental Implant, Implant Therapy, Immediate Dental Implant Placement, Delayed Implant
Heinrich-Heine University, Duesseldorf
Not applicable
50
Düsseldorf
2026-08-03
Not yet open
INJECTHEAL - Investigation of Chronic Wound Exudate and Biofilm
NCT07745764Chronic Ulcers: Non-healing Deep Cavity Wounds (e.g., Diabetic Foot Ulcers, Arterial Ulcers, Post-surgical Wound Healing Disorders)
Barbara Wolff-Winiski
Observational
72
Düsseldorf
2026-08-01
Not yet open
A Prospective Multicenter Cohort Study of Contemporary Menopausal Hormone Therapy and Cardiovascular Outcomes
NCT07394049Hormone Replacement Therapy, Cardiovascular Diseases, Hormone Replacement Therapy, Post-Menopausal, Menopause
Heinrich-Heine University, Duesseldorf
Observational
3,408
Berlin, Düsseldorf
2026-08-01
Not yet open
Mitral Valve Edge-to-Edge Repair in Patients With Exercise-Induced Severe Mitral Regurgitation
NCT07709208Heart Failure - NYHA II - IV, Mitral Regurgitation Functional
Jena University Hospital
Not applicable
246
Düsseldorf, Jena
2026-08
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)
DrugsObrixtamig·Etoposide·Carboplatin
Boehringer Ingelheim
Phase 3
390
Berlin, Bonn, Cologne, Dresden, Düsseldorf, Erlangen, Freiburg im Breisgau, Hamburg
2026-07-10
Recruiting
GRAnulomatous MAstitis REGistry Study
NCT07422870Idiopathic Granulomatous Mastitis, Granulomatous Mastitis
European Breast Cancer Research Association of Surgical Trialists
Observational
1,000
Düsseldorf, Lübeck
2026-07-01
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938Multiple Myeloma
DrugsCevostamab·Elotuzumab·Carfilzomib·Pomalidomide
Hoffmann-La Roche
Phase 3
380
Bad Saarow, Berlin, Düsseldorf, Frankfurt, Greifswald, Kiel
2026-06-23
Recruiting
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
NCT07647328ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Ribociclib
AstraZeneca
Phase 3
150
Berlin, Düsseldorf, Erlangen, Freiburg im Breisgau, Mönchengladbach, München, Paderborn, Trier
2026-06-15
Not yet open
Screening, Characterization, and Longitudinal Follow-up of Patients With Cardiac Amyloidosis
NCT07577466Amyloidosis Cardiac, Heart Failure, Cardiac MRI, Spectroscopic Analysis
Heinrich-Heine University, Duesseldorf
Observational
200
Düsseldorf
2026-06-15
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Munich, Würzburg, Bonn, Düsseldorf, Dresden, Leipzig, Beelitz, Berlin
2026-06-03
Recruiting
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
NCT07519902Persistent Corneal Epithelial Defect
DrugCenegermin
Dompé Farmaceutici S.p.A
Phase 3
150
Erlangen, Frankfurt am Main, Marburg, Cologne, Düsseldorf, Homburg, Berlin
2026-06-02
Not yet open
RELIEVE METAB Study
NCT07555925Heart Failure With Reduced Ejection Fraction (HFrEF)
Heinrich-Heine University, Duesseldorf
Not applicable
15
Düsseldorf
2026-06-01
Not yet open
A Study Testing Whether Low-Dose Radiation Could Help the Immune System and Possibly Improve Early-Onset Alzheimer's Disease.
NCT07564700Alzheimer Disease (AD), Early Onset Alzheimer Disease
Heinrich-Heine University, Duesseldorf
Not applicable
50
Düsseldorf
2026-05-15
Recruiting
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
NCT07538388Postinduction Hypotension
Universitätsklinikum Hamburg-Eppendorf
Not applicable
446
Berlin, Düsseldorf, Hamburg, München
2026-05-07
Recruiting
Glycolytic Phenotype (vLapeak) and Magnitude of Skeletal Muscle Hypertrophy After Resistance Training
NCT07721766Healthy Volunteers, Muscle Hypertrophy, Glycolysis, Moderately Trainend
Technical University of Munich
Not applicable
120
München, Cologne, Düsseldorf, Chemnitz, Leipzig
2026-05-04
Not yet open
A Study to Evaluate Clinical Benefit, Performance and Safety of Cochlear Implants in Adults
NCT07338864Hearing Loss, Hearing Implants
Cochlear
Observational
66
Düsseldorf
2026-05
Recruiting
Rapid Microaxial Flow Pump Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support
NCT07655479Cardiogenic Shock Post Myocardial Infarction
University Hospital of Cologne
Observational
115
Düsseldorf, Kiel, Cologne
2026-04-23
Recruiting
Controlling Hyperactive Immunity With Long-lived Lymphocytes
NCT07473154Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Autoimmune Rheumatologic Disease
Quell Therapeutics Limited
Phase 1/2
16
Düsseldorf, Erlangen
2026-04-10
Recruiting
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073Solid Tumors
DrugINCB161734
Incyte Corporation
Phase 3
588
Berlin, Bochum, Bonn, Cologne, Dresden, Düsseldorf, Essen, Frankfurt
2026-04-09
Recruiting
Improved Management of Patients With Recent-Onset Stable Chest Pain
NCT07476040Coronary Artery Disease (CAD)
Philipps University Marburg
Not applicable
3,369
Augsburg, Bad Neustadt an der Saale, Berlin, Cologne, Düsseldorf, Erlangen, Frankfurt, Giessen
2026-04-01
Not yet open
Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept
NCT07542678Relapsed /Refractory DLBCL
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
20
Heidelberg, Düsseldorf, Essen, Münster, Berlin
2026-04
Recruiting
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
NCT07571746Primary Membranous Nephropathy
DrugSurovatamig
AstraZeneca
Phase 2
43
Düsseldorf, München
2026-03-28
Recruiting
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
NCT07235592Primary Open Angle Glaucoma
Santen SAS
Observational
112
Düsseldorf, Tübingen
2026-03-19
Recruiting
BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System
NCT07118358Leadless Pacemaker, Bradycardia, AV Block, Cardiac Rhythm Disorder
Biotronik, Inc.
Not applicable
325
Bad Nauheim, Bad Oeynhausen, Düsseldorf
2026-03-16
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574Progressive Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 2
360
Freiburg im Breisgau, Mannheim, Tübingen, Ulm, Erlangen, Munich, Bochum, Düsseldorf
2026-03-10
Not yet open
Chronic and Acute Cardiovascular Diseases in Elderly Intensive Care Patients
NCT07385482Chronic Cardiovascular Disease, Acute Cardiovascular Disease, Frailty
Heinrich-Heine University, Duesseldorf
Observational
4,000
Düsseldorf
2026-03-01
Recruiting
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
NCT07454837Chronic Hepatitis D
DrugsBrelovitug·Bulevirtide
Mirum Pharmaceuticals, Inc.
Phase 2/3
120
Düsseldorf, Frankfurt, Hamburg, Hanover, Rostock
2026-02-26
Not yet open
10119473 -VIROMARKERS HDV Biomarkers Study
NCT07313358HDV Infection
University of Rome Tor Vergata
Observational
220
Düsseldorf
2026-02-20
Recruiting
A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
NCT07435428Moderate to Severe Glabellar Lines
DrugCorabotase
Ipsen
Phase 3
1,300
Darmstadt, Düsseldorf, Hamburg, Kassel, Mahlow, München, Potsdam
2026-02-18
Recruiting
T-cell Therapy in Patients With PML
NCT06990087Progressive Multifocal Leucoencephalopathy (PML)
Hannover Medical School
Phase 2
23
München, Marburg, Hanover, Düsseldorf, Essen, Kiel
2026-02-06
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511Multiple Myeloma
DrugsRamantamig·Teclistamab
Janssen Research & Development, LLC
Phase 3
400
Düsseldorf, Heidelberg, Jena, Würzburg
2026-02-04
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Freiburg im Breisgau, Frankfurt am Main, Düsseldorf
2026-01-30
Recruiting
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
NCT07266402Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
240
Augsburg, Berlin, Buxtehude, Darmstadt, Dresden, Düsseldorf, Erlangen, Göttingen
2026-01-15
Recruiting
Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart Devices
NCT07273903CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Heinrich-Heine University, Duesseldorf
Observational
35
Düsseldorf, Münster
2026-01-15
Active, closed
COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)
NCT07455097Intermediate-risk Prostate Cancer, High-risk Prostate Cancer
Heinrich-Heine University, Duesseldorf
Observational
600
Düsseldorf, Herne, Munich, Tübingen
2026-01-01
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
DrugsFolfiri·Pumitamig·Folfox·Bevacizumab
Bristol-Myers Squibb
Phase 2/3
990
Erlangen, Hanover, Dresden, Berlin, Bochum, Chemnitz, Düsseldorf, Frankfurt
2025-12-31
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin
AstraZeneca
Phase 3
1,100
Berlin, Bonn, Detmold, Dresden, Düsseldorf, Essen, Frankfurt am Main, Hamburg
2025-12-29
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336Breast Neoplasms, Neoplasm Metastasis
DrugsTersolisib·Exemestane·Anastrozole·Ribociclib
Eli Lilly and Company
Phase 3
800
Berlin, Bottrop, Cologne, Dessau, Donauwörth, Dresden, Düsseldorf, Erlangen
2025-12-22
Recruiting
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
NCT07237256Breast Cancer
UNICANCER
Phase 3
3,902
Aachen, Augsburg, Bad Nauheim, Berlin, Bremen, Cottbus, Dresden, Düsseldorf
2025-12-18
Recruiting
Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
NCT07301736Asthma
Chiesi Farmaceutici S.p.A.
Phase 2
780
Ahrensburg, Berlin, Cottbus, Delitzsch, Düsseldorf, Hamburg, Ibbenbueren, Leipzig
2025-12-17
Recruiting
NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy
NCT07365930Hepatocellular Carcinoma (HCC)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Observational
350
Düsseldorf
2025-12-17
Recruiting
DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
NCT07110038Penile Squamous Cell Carcinoma (PSCC)
DrugsAvelumab·Enfortumab Vedotin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
25
Dresden, Düsseldorf, Mainz, Mannheim, Munich, Regensburg, Rostock, Tübingen
2025-12-16
Recruiting
Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
NCT06722183Colorectal Cancer
DrugTislelizumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
33
Amberg, Berlin, Düsseldorf, Essen, Frankfurt am Main, Hamburg, Mainz, München
2025-12-16
Recruiting
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
NCT07280585Polycystic Kidney, Autosomal Dominant
DrugDapagliflozin
University of Cologne
Phase 3
420
Stuttgart, Nuremberg, Aachen, Berlin, Cologne, Dortmund, Dresden, Düsseldorf
2025-12-16
Not yet open
VIROMARKERS GA n.101194735 - CMV and TTV Biomarkers Study Protocol
NCT07286461Allogeneic Hematopoietic Stem Cell Transplantation Recipient, CMV
University of Rome Tor Vergata
Observational
290
Düsseldorf
2025-12-15
Recruiting
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
NCT07221851Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Ascendis Pharma A/S
Phase 3
186
Düsseldorf, Hanover, Tübingen
2025-12-12
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Bad Saarow, Bielefeld, Bonn, Cologne, Dresden, Duisburg, Düsseldorf, Erlangen
2025-12-12
Recruiting
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
NCT07226999Small Cell Lung Cancer (SCLC)
DrugsPF-08634404·Atezolizumab
Pfizer
Phase 2/3
550
Düsseldorf, Frankfurt am Main
2025-12-09
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab
AstraZeneca
Phase 3
1,100
Aachen, Berlin, Bonn, Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Hamburg
2025-12-04
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
NCT07230691Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Observational
380
Aschaffenburg, Bielefeld, Bochum, Chemnitz, Cologne, Düsseldorf, Essen, Hamburg
2025-12-03
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
650
Düsseldorf, Halle, Westerstede
2025-12-02
Recruiting
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
NCT06847542Neovascular Age-related Macular Degeneration
DrugRanibizumab
Hoffmann-La Roche
Phase 3
250
Chemnitz, Düsseldorf, Göttingen, Hanover, Rostock, Würzburg
2025-11-27
Recruiting
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958Acute Myeloid Leukemias
DrugRevumenib
Syndax Pharmaceuticals
Phase 3
468
Heidelberg, Stuttgart, Tübingen, Düsseldorf, Herne, Minden, Chemnitz, Jena
2025-11-25
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
DrugPrasinezumab
Hoffmann-La Roche
Phase 3
900
Beelitz, Berlin, Bochum, Dresden, Düsseldorf, Erlangen, Freiburg im Breisgau, Hanover
2025-11-24
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Frankfurt, Düsseldorf, Witten, Torgau
2025-11-03
Not yet open
Adaptation and Validation of a Patient-centered Outcome Scale for People in the Intensive Care Unit (IPOS-ICU)
NCT07004920Intensive Care Unit Patients
Heinrich-Heine University, Duesseldorf
Observational
500
Düsseldorf
2025-11-01
Recruiting
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT07197307Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B
Universität Münster
Phase 2
120
Aachen, Augsburg, Berlin, Bielefeld, Chemnitz, Düsseldorf, Erlangen, Essen
2025-10-31
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
DrugAvacincaptad Pegol
ONL Therapeutics
Phase 2
324
Ahaus, Bonn, Düsseldorf, Frankfurt am Main, Marburg, Würzburg
2025-10-28
Recruiting
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
NCT06856837Metastatic Colorectal Cancer
DrugsLonsurf·Trifluridine/Tipiracil·Fruquintinib·Avastin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
140
Amberg, Bad Saarow, Berlin, Bochum, Düsseldorf, Essen, Frankfurt, Frankfurt am Main
2025-10-27
Recruiting
Existential Distress in Advanced Cancer: Comparing a Short-term Psychodynamic Psychotherapy (ORPHYS) to Treatment as Usual (TAU)
NCT07312760Advanced Cancer, Various, NOS
Universitätsklinikum Hamburg-Eppendorf
Not applicable
160
Düsseldorf, Hamburg, Würzburg
2025-10-24
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
DrugsMIRV·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
Eli Lilly and Company
Phase 3
1,630
Aachen, Berlin, Bonn, Cologne, Dresden, Düsseldorf, Erlangen, Essen
2025-10-22
Recruiting
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
NCT07206056Progressive Metastatic Castrate Resistant Prostate Cancer
DrugLuxdegalutamide
Novartis Pharmaceuticals
Phase 1/2
188
Düsseldorf, Jena
2025-10-15
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
4,500
Bad Oeynhausen, Berlin, Brandenburg, Dresden, Düsseldorf, Frankfurt, Hanover, Heidelberg
2025-10-15
Recruiting
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
NCT06997588PIK3CA-related Overgrowth Spectrum (PROS)
DrugAlpelisib
Novartis Pharmaceuticals
Phase 2
104
Freiburg im Breisgau, Düsseldorf, Leipzig, Halle, Berlin, Stuttgart
2025-10-09
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
DrugPonsegromab
Pfizer
Phase 2/3
982
München, Düsseldorf, Dresden, Leipzig, Berlin
2025-10-03
Active, closed
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)
NCT07210463Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
DrugXeomin
Merz Aesthetics GmbH
Phase 3
300
Munich, Blankenfelde-Mahlow, Potsdam, Friedrichsdorf, Kassel, Bochum, Düsseldorf, Drensteinfurt
2025-10-01
Recruiting
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
NCT07197866Multiple System Atrophy
DrugEmrusolmin
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
200
Dresden, Düsseldorf, Kassel, Marburg, München, Münster
2025-09-30
Active, closed
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
NCT07187375Congenital Adrenal Hyperplasia
DrugCrinecerfont
Neurocrine Switzerland GmbH
Phase 2
7
Berlin, Düsseldorf, Heidelberg
2025-09-30
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsMevrometostat·Xtandi·Enzalutamide
Pfizer
Phase 3
1,000
Heidelberg, Nürtingen, Ulm, Mettmann, Lübeck, Berlin, Düsseldorf, Hamburg
2025-09-28
Recruiting
Impella Pump Return Study to Analyze Deposits and Biomaterial in Used Pumps
NCT06765226Heart Failure
Abiomed Inc.
Observational
200
Heidelberg, Düsseldorf, Dresden, Leipzig, Berlin, Cologne, Essen
2025-09-21
Recruiting
GEL & MEDication Dysphagia
NCT07254663Neurological Diseases or Conditions, Healthy Participants
Heinrich-Heine University, Duesseldorf
Observational
500
Düsseldorf, Münster, Onsabrück
2025-09-15
Recruiting
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
400
Berlin, Bonn, Braunschweig, Bremen, Cologne, Düsseldorf, Essen, Freiburg im Breisgau
2025-09-13
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
600
Esslingen am Neckar, Augsburg, München, Frankfurt am Main, Langen, Hanover, Düsseldorf, Essen
2025-09-11
Recruiting
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
NCT07115745Refractory Autoimmune Diseases
DrugsTocilizumab·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
125
Düsseldorf, Kiel, Berlin, Dresden, Hamburg
2025-09-04
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
DrugsJNJ-87189401·Pasritamig
Janssen Research & Development, LLC
Phase 3
1,203
Braunschweig, Duisburg, Düsseldorf, Essen, Frankfurt am Main, Hamburg, Heidelberg, München
2025-09-02
Recruiting
Biological Determinants and Neural Compensation of Dysphagia in Parkinson's Disease
NCT07299448Parkinsons Disease (PD), Oropharyngeal Dysphagia
Heinrich-Heine University, Duesseldorf
Observational
100
Düsseldorf
2025-09-01
Recruiting
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
NCT07200908Chronic Hepatitis D Infection
DrugBrelovitug
Mirum Pharmaceuticals, Inc.
Phase 3
172
Frankfurt, Rostock, Düsseldorf, Hanover
2025-08-27
Recruiting
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
NCT07264426Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
DrugEfgartigimod PH20
argenx
Observational
200
Berlin, Bochum, Cologne, Düsseldorf, Frankfurt, Giessen, Göttingen, Hamburg
2025-08-11
By invitation
Transfemoral TAVI With or Without Coronary Angiogram in Patients With Severe Aortic Stenosis (PURE TAVI)
NCT06898086Severe Aortic Stenosis
Rede Optimus Hospitalar SA
Not applicable
620
Düsseldorf, Essen, Freiburg im Breisgau, Lübeck, Ulm
2025-08-08
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
DrugBaxdrostat
AstraZeneca
Phase 3
250
Berlin, Düsseldorf, Kaiserslautern, München, Reinfeld (Holstein), Würzburg
2025-08-07
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
DrugsPrednisolone/Prednisone·Saruparib·Abiraterone
AstraZeneca
Phase 3
700
Augsburg, Berlin, Braunschweig, Cologne, Dresden, Duisburg, Düsseldorf, Essen
2025-08-06
Recruiting
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
NCT06780111Esophageal Squamous Cell Carcinoma
DrugsIfinatamab Deruxtecan·Sacituzumab tirumotecan·Leucovorin·Adrucil
Merck Sharp & Dohme LLC
Phase 1/2
298
Erdgeschoss, Düsseldorf, Dresden
2025-07-30
Recruiting
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT06911502Follicular Lymphoma
DrugsPrednisone/Prednisolone·Golcadomide·Bendamustine·Vincristine
Celgene
Phase 3
400
Ulm, Augsburg, Göttingen, Dortmund, Düsseldorf, Münster, Homburg, Erfurt
2025-07-28
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634Breast Cancer
DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole
Celcuity Inc
Phase 3
1,180
Düsseldorf, Mainz, Saarbrücken, Wuppertal
2025-07-24
Recruiting
METABolic Deterioration in HTX Determines Outcomes
NCT07372820Heart Transplantation
Heinrich-Heine University, Duesseldorf
Observational
270
Düsseldorf
2025-07-24
Recruiting
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT07064759Neovascular Age-Related Macular Degeneration (nAMD)
DrugsEYLEA (aflibercept)·4D-150 IVT
4D Molecular Therapeutics
Phase 3
480
Düsseldorf, Frankfurt, Neubrandenburg
2025-07-22
Recruiting
AI-based pCR Assessment/Prediction in HER2-Positive BC Using PET/MRI
NCT06708910HER2 Positive Breast Carcinoma
Heinrich-Heine University, Duesseldorf
Observational
460
Düsseldorf
2025-07-18
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
NCT07011745Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
426
Düsseldorf, Halle, Westerstede
2025-07-16
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Cologne, Düsseldorf, Leipzig, München
2025-07-16
Recruiting
Follitropin Delta in Long GnRH-agonist Protocol
NCT06995261Infertility (IVF Patients), Infertility, Infertility Drugs
Prof. Dr. med. M.Sc. Georg Griesinger
Observational
350
Düsseldorf, Saarbrücken, Kiel, Lübeck
2025-07-09
Active, closed
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556Metastatic Hormone-sensitive Prostate Cancer
DrugsLuxdegalutamide·Abiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 2
168
Düsseldorf, Hamburg, Lübeck, Nürtingen
2025-07-07
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Bad Berka, Bad Neustadt an der Saale, Bad Segeberg, Berlin, Bonn, Detmold, Dresden, Düsseldorf
2025-06-25
Recruiting
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
NCT05903833Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer, Locally Advanced Vulvar Cancer
DrugsLenvatinib·Pembrolizumab
AGO Research GmbH
Phase 2
42
Augsburg, Bad Homburg, Dresden, Düsseldorf, Essen, Göttingen, Hamburg, Hanau
2025-06-24
Recruiting
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
NCT06885034Gastrointestinal Neoplasms
DrugRisvutatug Rezetecan
GlaxoSmithKline
Phase 1/2
451
Bochum, Düsseldorf, Frankfurt, Lübeck, München
2025-06-11
Recruiting
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
NCT06962839Macular Edema
Boehringer Ingelheim
Phase 2
300
Dresden, Düsseldorf, Leipzig, Mannheim, Münster
2025-06-05
Rows per page Showing 1–100 of 420
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/d-sseldorf

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 420 of those studies with a site in Düsseldorf.

How many clinical trials are recruiting in Düsseldorf?

240 of the 420 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 20 have not yet opened recruitment, 153 are active but closed to new participants, and 7 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Düsseldorf), 420 studies
PhaseStudiesRecruitingShare
Phase 31426633.8%
Observational1117426.4%
Not applicable724217.1%
Phase 2532812.6%
Phase 1/220154.8%
Phase 2/312102.9%
Phase 1841.9%
Phase 4210.5%

Most active sponsors

Lead sponsors with the most studies (Düsseldorf)
Lead sponsorStudiesRecruiting
Heinrich-Heine University, Duesseldorf4329
AstraZeneca2013
Hoffmann-La Roche136
Merck Sharp & Dohme LLC137
Boston Scientific Corporation87
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest86
Janssen Research & Development, LLC83
Celgene74
German Diabetes Center76
Bristol-Myers Squibb64
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.